Highlights Compugen Ltd.

Equities

CGEN

IL0010852080

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-03 pm EDT			5-day change	1st Jan Change
2.11 ^USD	-2.31%		+11.05%	+6.57%

Mar. 08	Truist Securities Adjusts Price Target on Compugen to $5 From $4, Maintains Buy Rating	MT
Mar. 05	Transcript : Compugen Ltd., Q4 2023 Earnings Call, Mar 05, 2024

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Earnings Flash (CGEN) COMPUGEN Reports Q4 Revenue $33.5M	Mar. 05	MT
Earnings Flash (CGEN) COMPUGEN Posts Q4 EPS $0.11	Mar. 05	MT
Earnings Flash (CW9) COMPUGEN Posts Q4 EPS $0.11	Mar. 05	MT
Compugen Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 05	CI
Exchange-Traded Funds, US Equities Rise Pre-Bell Tuesday as Investors Continue to Hope for Federal Reserve Rate Cuts Soon	Dec. 19	MT
Gilead Sciences, Compugen Sign Exclusive Licensing Deal for Pre-Clinical Immunotherapy Program; Compugen Shares Soar	Dec. 19	MT
Compugen Will Be Eligible to Receive $10 Million Milestone Payment Upon Dosing of First Patient in Astrazeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer	Dec. 19	CI
Gilead Sciences, Inc. and Compugen Ltd. Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program	Dec. 19	CI
Compugen Gets Nasdaq Non-Compliance Notice on Minimum Bid Price Rule	Nov. 03	MT
Compugen Ltd. Announces to Present New Data At Sitc 2023 Suggesting Leading Edge of Anti-Il18 Binding Protein Antibody, Com503, in Treating Cancer	23-10-31	CI
Compugen Gets Japanese Patent for Cancer Combination Therapy	23-10-02	MT
Compugen Expands Intellectual Property with New Japanese Patent for the Triple Combination of Anti-PVRIG, TIGIT and PD-1 Antibody for the Treatment of Cancer	23-10-02	CI
Compugen Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07	CI
Compugen Says European Patent Office Rules in Favor of Maintaining Claims to Patent on Cancer Treatment	23-07-17	MT
Compugen Wins on PVRIG European Patent Opposition Pursued by GSK and a Third Party	23-07-17	CI
Compugen Ltd. Doses First Patient in Triple Immunotherapy Combination COM701, COM902 and Pembrolizumab Platinum Resistant Ovarian Cancer Proof-Of-Concept Study	23-06-22	CI
Compugen Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Compugen Ltd. to Present Data on its Lead Pre-Clinical Asset COM503 in an Oral Presentation at the 20th CIMT Annual Meeting	23-04-26	CI
Compugen Doses First Patient in Triple Combination COM701, COM902 and Pembrolizumab MSS CRC Proof-Of-Concept Study	23-03-06	CI
OTORIO and Compugen Signs Global Partnership to Enhance Security for OT Operations	23-02-28	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Compugen Ltd.

Equities

CGEN

IL0010852080

Highlights

Filters